<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nogr</journal-id><journal-title-group><journal-title xml:lang="ru">Экспериментальная и клиническая гастроэнтерология</journal-title><trans-title-group xml:lang="en"><trans-title>Experimental and Clinical Gastroenterology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-8658</issn><publisher><publisher-name>«Global Media Technologies»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/1682-8658-ecg-207-11-204-210</article-id><article-id custom-type="elpub" pub-id-type="custom">nogr-2209</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНАЯ ГАСТРОЭНТЕРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL GASTROENTEROLOGY</subject></subj-group></article-categories><title-group><article-title>Роль перлекана в ремоделировании внеклеточного матрикса печени, легких и селезенки мышей после введения вакцины БЦЖ и липосомальной формы декстразида</article-title><trans-title-group xml:lang="en"><trans-title>The role of perlecan in remodeling the extracellular matrix of the liver, lungs and spleen of mice after administration of BCG vaccine and the liposome-encapsulated dextrazide</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4051-8854</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ким</surname><given-names>Л. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Kim</surname><given-names>L. B.</given-names></name></name-alternatives><email xlink:type="simple">lenkim@centercem.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9599-3049</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Путятина</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Putyatina</surname><given-names>A. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1565-5248</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Русских</surname><given-names>Г. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Russkikh</surname><given-names>G. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Федеральный исследовательский центр фундаментальной и трансляционной медицины»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Research Center of Fundamental and Translational Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>23</day><month>01</month><year>2023</year></pub-date><volume>0</volume><issue>11</issue><fpage>204</fpage><lpage>210</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ким Л.Б., Путятина А.Н., Русских Г.С., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Ким Л.Б., Путятина А.Н., Русских Г.С.</copyright-holder><copyright-holder xml:lang="en">Kim L.B., Putyatina A.N., Russkikh G.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nogr.org/jour/article/view/2209">https://www.nogr.org/jour/article/view/2209</self-uri><abstract><p>Несмотря на известные достижения в диагностике туберкулёза, вопросы механизма развития и лечения фибротических осложнений остаются актуальными и нуждаются в решении. Цель исследования - изучить содержание перлекана и выяснить его участие в ремоделировании внеклеточного матрикса органов мышей с туберкулёзным воспалением и при введении им противотуберкулёзной композиции. Материалы и методы. Эксперимент проводили на мышах-самцах линии BALB/с, которые были разделены на 4 группы по 5 особей в каждой. Всем животным за исключением интактных мышей (группа 1) для моделирования генерализованного туберкулёзного процесса однократно ретроорбитально вводили вакцину БЦЖ (0,5 мг микробных тел в 0,2 мл 0,9% раствора NaCl). Через 6 мес после инфицирования в течение 3 мес мышам группы 2 внутриперитонеально вводили 50 мкл 0,9% раствора NaCl, группы 3 - внутриперитонеально 50 мкл раствора липосомальной формы декстразида (ЛФДЗ, конъюгат изониазида и окисленного декстрана, заключенный в липосомы), группы 4 - ингаляционно подавали раствор ЛФДЗ, распыляя в камере через небулайзер в течение 5 мин из расчёта 50 мкл раствора на животное. После последнего введения раствора NaCl и ЛФДЗ мышей выводили из эксперимента, забирали органы, готовили гомогенаты тканей. Измеряли содержание перлекана, гиалуронана, белково-связанного гидроксипролина, тканевых ингибиторов металлопротеиназ (ТИМП-1, ТИМП-2) и активность матриксных металлопротеиназ (ММП), гиалуронидаз, α2-макроглобулина. Результаты. Во всех органах инфицированных мышей было увеличено содержание перлекана, гиалуронана, белково-связанного гидроксипролина, ТИМП-1, ТИМП-2, активированы ММП, гиалуронидазы, α2-макроглобулин. Независимо от способа введения ЛФДЗ уменьшалась выраженность фиброза за счет снижения содержания гиалуронана во всех органах и белково-связанного гидроксипролина в лёгких. Перлекан при внутриперитонеальном введении участвует в фиброзировании селезёнки, ингаляционном - отражает выраженность фиброза печени. Заключение. Корреляции перлекана с компонентами внеклеточного матрикса отражают участие в регуляции фиброза органов при БЦЖ-индуцированном воспалении.</p></abstract><trans-abstract xml:lang="en"><p>Despite significant advances in the diagnosis of tuberculosis, the issues of the mechanism of development and treatment of fibrotic manifestations are relevant and take place in the treatment. The aim of the study was to study the content of perlecane and to find out its participation in the remodeling of the extracellular matrix of the organs of mice with tuberculous inflammation and when they were injected with an antitubercular composition. Materials and methods. The experiment was carried out on male mice of the BALB/c line, which were divided into 4 groups of 5 individuals each. All animals, with the exception of intact mice (group 1), were retroorbitally injected with BCG vaccine once (0.5 mg of microbial bodies in 0.2 ml of 0.9% NaCl solution) to simulate a generalized tuberculosis process. After infection 6 mo for 3 mo, group 2 mice were intraperitoneally injected with 50 µl of 0.9% NaCl solution, group 3 - intraperitoneally with 50 µl of liposome-encapsulated dextrazide solution (LEDZ, isoniazid conjugate and oxidized dextran enclosed in liposomes), group 4 - LEDZ solution was inhaled by spraying in the chamber through a nebulizer for 5 min at the rate of 50 µl of solution per animal. After the last administration of the NaCl and LEDZ solution, mice were removed from the experiment, organs were taken, and tissue homogenates were prepared. The content of perlecane, hyaluronan, protein-bound hydroxyproline, tissue metalloproteinase inhibitors (TIMP-1, TIMP-2) and the activity of matrix metalloproteinases (MMP), hyaluronidases, α2-macroglobulin were measured. Results. In all organs of infected mice, the content of perlecan, hyaluronan, protein-bound hydroxyproline, TIMP-1, TIMP-2 was increased, MMP, hyaluronidase, α2-macroglobulin were activated. Regardless of the method of administration of LEDZ, the severity of fibrosis decreased due to a decrease in the content of hyaluronan in all organs and protein-bound hydroxyproline in the lungs. Perlecan with intraperitoneal administration is involved in fibrosis of the spleen, inhalation - reflects the severity of liver fibrosis. Conclusion. Correlations of perlecan with extracellular matrix components reflect participation in the regulation of fibrosis of organs in BCG-induced inflammation.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>туберкулёз</kwd><kwd>липосомальная форма декстразида</kwd><kwd>перлекан</kwd><kwd>гиалуронан</kwd><kwd>гидроксипролин/коллаген</kwd><kwd>α2-макроглобулин</kwd><kwd>матриксные металлопротеиназы/тканевые ингибиторы металлопротеиназ</kwd><kwd>гиалуронидазы</kwd><kwd>органы мышей</kwd><kwd>фиброз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>tuberculosis</kwd><kwd>liposome-encapsulated dextrazide</kwd><kwd>perlecan</kwd><kwd>hyaluronan</kwd><kwd>hydroxyproline/collagen</kwd><kwd>α2-macroglobulin</kwd><kwd>matrix metalloproteinases/tissue metalloproteinase inhibitors</kwd><kwd>hyaluronidases</kwd><kwd>mouse organs</kwd><kwd>fibrosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Global tuberculosis report 2020. Geneva: World Health Organization; 2020.</mixed-citation><mixed-citation xml:lang="en">Global tuberculosis report 2020. Geneva: World Health Organization; 2020.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Shkurupiy V. A., Kim L. B., Potapova O. V., et al. Fibrogenesis in granulomas and lung interstitium in tuberculous inflammation in mice. Bull. Exp. Biol. Med. 2014;156(6):731-5. doi: 10.1007/s10517-014-2435-y.</mixed-citation><mixed-citation xml:lang="en">Shkurupiy V. A., Kim L. B., Potapova O. V., et al. Fibrogenesis in granulomas and lung interstitium in tuberculous inflammation in mice. Bull. Exp. Biol. Med. 2014;156(6):731-5. doi: 10.1007/s10517-014-2435-y.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lord M. S., Tang F., Rnjak-Kovacina J., et al. The multifaceted roles of perlecan in fibrosis. Matrix Biol. 2018;68-69:150-66. doi: 10.1016/j.matbio.2018.02.013.</mixed-citation><mixed-citation xml:lang="en">Lord M. S., Tang F., Rnjak-Kovacina J., et al. The multifaceted roles of perlecan in fibrosis. Matrix Biol. 2018;68-69:150-66. doi: 10.1016/j.matbio.2018.02.013.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Karsdal M. A., Nielsen S. H., Leeming D. J., et al. The good and the bad collagens of fibrosis - Their role in signaling and organ function. Adv. Drug Deliv. Rev. 2017;121:43-56. doi: 10.1016/j.addr.2017.07.014.</mixed-citation><mixed-citation xml:lang="en">Karsdal M. A., Nielsen S. H., Leeming D. J., et al. The good and the bad collagens of fibrosis - Their role in signaling and organ function. Adv. Drug Deliv. Rev. 2017;121:43-56. doi: 10.1016/j.addr.2017.07.014.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Karsdal M. A., Daniels S. J., Holm Nielsen S., et al. Collagen biology and non-invasive biomarkers of liver fibrosis. Liver Int. 2020;40(4):736-50. doi: 10.1111/liv.14390.</mixed-citation><mixed-citation xml:lang="en">Karsdal M. A., Daniels S. J., Holm Nielsen S., et al. Collagen biology and non-invasive biomarkers of liver fibrosis. Liver Int. 2020;40(4):736-50. doi: 10.1111/liv.14390.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Giannandrea M., Parks W. C. Diverse functions of matrix metalloproteinases during fibrosis. Dis. Model Mech. 2014;7(2):193-203. doi: 10.1242/dmm.012062.</mixed-citation><mixed-citation xml:lang="en">Giannandrea M., Parks W. C. Diverse functions of matrix metalloproteinases during fibrosis. Dis. Model Mech. 2014;7(2):193-203. doi: 10.1242/dmm.012062.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Iozzo R. V., Schaefer L. Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol. 2015;42:11-55. doi: 10.1016/j.matbio.2015.02.003.</mixed-citation><mixed-citation xml:lang="en">Iozzo R. V., Schaefer L. Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol. 2015;42:11-55. doi: 10.1016/j.matbio.2015.02.003.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Farach-Carson M.C., Warren C. R., Harrington D. A., Carson D. D. Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue. Matrix Biol. 2014;34:64-79. doi:10.1016/j.matbio.2013.08.004.</mixed-citation><mixed-citation xml:lang="en">Farach-Carson M.C., Warren C. R., Harrington D. A., Carson D. D. Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue. Matrix Biol. 2014;34:64-79. doi:10.1016/j.matbio.2013.08.004.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">McCarthy K. J. The basement membrane proteoglycans perlecan and agrin: something old, something new. Curr. Top Membr. 2015;76:255-303. doi: 10.1016/bs.ctm.2015.09.001.</mixed-citation><mixed-citation xml:lang="en">McCarthy K. J. The basement membrane proteoglycans perlecan and agrin: something old, something new. Curr. Top Membr. 2015;76:255-303. doi: 10.1016/bs.ctm.2015.09.001.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Arikawa-Hirasawa E. Role of perlecan in development and diseases. Adv. Dev. Biol. 2005;15:65-80. doi: 10.1016/S1574-3349(05)15002-9.</mixed-citation><mixed-citation xml:lang="en">Arikawa-Hirasawa E. Role of perlecan in development and diseases. Adv. Dev. Biol. 2005;15:65-80. doi: 10.1016/S1574-3349(05)15002-9.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Melrose J. Perlecan, a modular instructive proteoglycan with diverse functional properties.Int. J. Biochem. Cell Biol. 2020;128:105849. doi: 10.1016/j.biocel.2020.105849.</mixed-citation><mixed-citation xml:lang="en">Melrose J. Perlecan, a modular instructive proteoglycan with diverse functional properties.Int. J. Biochem. Cell Biol. 2020;128:105849. doi: 10.1016/j.biocel.2020.105849.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kim L. B., Putyatina A. N., Russkikh G. S., Shkurupy V. A. Antifibrotics effect of liposome-encapsulated composition of oxidized dextran and isonicotinic acid hydrazide in mice with BCG-induced granulomatosis depends on administration route. Bull. Exp. Biol. Med. 2020;169(1):71-6. doi: 10.1007/s10517-020-04827-4.</mixed-citation><mixed-citation xml:lang="en">Kim L. B., Putyatina A. N., Russkikh G. S., Shkurupy V. A. Antifibrotics effect of liposome-encapsulated composition of oxidized dextran and isonicotinic acid hydrazide in mice with BCG-induced granulomatosis depends on administration route. Bull. Exp. Biol. Med. 2020;169(1):71-6. doi: 10.1007/s10517-020-04827-4.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kim L. B., Putyatina A. N., Russkikh G. S., Shkurupy V. A. Specific parameters of extracellular matrix remodeling of liver and lungs of mice with BCG granulomatosis during chronic inflammation depending on the method of administration of liposomal oxidized dextran. Tuberculosis and Lung Diseases. 2021;99(8):40-6. (In Russ.) doi: 10.21292/2075-1230-2021-99-8-40-46.@@ Ким Л. Б., Путятина А. Н., Русских Г. С., Шкурупий В. А. Особенности ремоделирования внеклеточного матрикса печени и лёгких мышей с БЦЖ-гранулематозом в периоде хронического воспаления в зависимости от способа введения липосомальной формы декстразида // Туберкулёз и болезни лёгких. - 2021. - Т. 99, № 8. - С. 40-6.</mixed-citation><mixed-citation xml:lang="en">Kim L. B., Putyatina A. N., Russkikh G. S., Shkurupy V. A. Specific parameters of extracellular matrix remodeling of liver and lungs of mice with BCG granulomatosis during chronic inflammation depending on the method of administration of liposomal oxidized dextran. Tuberculosis and Lung Diseases. 2021;99(8):40-6. (In Russ.) doi: 10.21292/2075-1230-2021-99-8-40-46.@@ Ким Л. Б., Путятина А. Н., Русских Г. С., Шкурупий В. А. Особенности ремоделирования внеклеточного матрикса печени и лёгких мышей с БЦЖ-гранулематозом в периоде хронического воспаления в зависимости от способа введения липосомальной формы декстразида // Туберкулёз и болезни лёгких. - 2021. - Т. 99, № 8. - С. 40-6.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Shkurupii V. A., Kim L. B., Potapova O. V. et al. Study of fibrotic complications and hydroxyproline content in mouse liver at different stages of generalized BCG-induced granulomatosis. Bull. Exp. Biol. Med. 2014;157(4):466-9. doi: 10.1007/s10517-014-2592-z.</mixed-citation><mixed-citation xml:lang="en">Shkurupii V. A., Kim L. B., Potapova O. V. et al. Study of fibrotic complications and hydroxyproline content in mouse liver at different stages of generalized BCG-induced granulomatosis. Bull. Exp. Biol. Med. 2014;157(4):466-9. doi: 10.1007/s10517-014-2592-z.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kim L. B., Putyatina A. N., Russkikh G. S., Shkurupy V. A. Peculiarities of collagen turnover in aging BALB/c mice. Bull. Exp. Biol. Med. 2020;169(1):100-3. doi: 10.1007/s10517-020-04833-6.</mixed-citation><mixed-citation xml:lang="en">Kim L. B., Putyatina A. N., Russkikh G. S., Shkurupy V. A. Peculiarities of collagen turnover in aging BALB/c mice. Bull. Exp. Biol. Med. 2020;169(1):100-3. doi: 10.1007/s10517-020-04833-6.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Miller J. D., Stevens E. T., Smith D. R., et al. Perlecan: a major IL-2-binding proteoglycan in murine spleen. Immunol. Cell Biol. 2008;86(2):192-9. doi: 10.1038/sj.icb.7100128.</mixed-citation><mixed-citation xml:lang="en">Miller J. D., Stevens E. T., Smith D. R., et al. Perlecan: a major IL-2-binding proteoglycan in murine spleen. Immunol. Cell Biol. 2008;86(2):192-9. doi: 10.1038/sj.icb.7100128.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Asplund A., Stillemark-Billton P., Larsson E., et al. Hypoxic regulation of secreted proteoglycans in macrophages. Glycobiology. 2010;20(1):33-40. doi: 10.1093/glycob/cwp139.</mixed-citation><mixed-citation xml:lang="en">Asplund A., Stillemark-Billton P., Larsson E., et al. Hypoxic regulation of secreted proteoglycans in macrophages. Glycobiology. 2010;20(1):33-40. doi: 10.1093/glycob/cwp139.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Scotton C. J., Chambers R. C. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest. 2007;132(4):1311-21. doi: 10.1378/chest.06-2568.</mixed-citation><mixed-citation xml:lang="en">Scotton C. J., Chambers R. C. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest. 2007;132(4):1311-21. doi: 10.1378/chest.06-2568.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hinz B. The myofibroblast: paradigm for a mechanically active cell. J. Biomech. 2010;43(1):146-55. doi: 10.1016/j.jbiomech.2009.09.020.</mixed-citation><mixed-citation xml:lang="en">Hinz B. The myofibroblast: paradigm for a mechanically active cell. J. Biomech. 2010;43(1):146-55. doi: 10.1016/j.jbiomech.2009.09.020.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Albeiroti S., Soroosh A., de la Motte C. A. Hyaluronan’s role in fibrosis: a pathogenic factor or a passive player? Biomed. Res.Int. 2015;2015:790203. doi: 10.1155/2015/790203.</mixed-citation><mixed-citation xml:lang="en">Albeiroti S., Soroosh A., de la Motte C. A. Hyaluronan’s role in fibrosis: a pathogenic factor or a passive player? Biomed. Res.Int. 2015;2015:790203. doi: 10.1155/2015/790203.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
